Mu.Ta.Lig - COST ACTION CA15135


14 June 2016


General information

Name: Jan
Surname: Korabecny
Cell phone number with international prefix: +420-724-770-956
Country: Czech Republic
Affiliation: Biomedical Research Center, Faculty Hospital in Hradec Kralove
Gender: M
Year of the PhD title: 2012
Personal web page:
Previous COST participation: No


List of 10 selected publications within last 5 years

1. Zemek, F.; Korabecny, J.; Sepsova, V.; Karasova-Zdarova, J.; Musilek, K.; Kuca, K. Albumin and Alpha 1-Acid Glycoprotein; An Old Acquaintance. Expert Opin. Drug Metab. Toxicol., 2013, 9, 943-954.
2. Soukup, O.; Jun, D.; Karasova-Zdarova, J.; Patocka, J.; Musilek, K.; Korabecny, J.; Krusek, J.; Kaniakova, M.; Sepsova, V.; Mandikova, J.; Trejtnar, F.; Pohanka, M.; Drtinova, L.; Pavlik, M.; Tobin, G.; Kuca, K. A resurrection of 7-MEOTA: a comparison with tacrine. Curr. Alzheimer Res., 2013, 10, 893-906.
3. Nepovimova, E.; Uliassi, E.; Korabecny, J.; Peña-Altamira, L.E.; Samez, S.; Pesaresi, A.; Garcia, G.E.; Bartolini, M.; Andrisano, V.; Bergamini, C.; Fato, R.; Lamba, D.; Roberti, M. Kuca, K.; Monti, B.; Bolognesi, M.L. Multitarget drug design strategy: quinone-tacrine hybrids designed to block amyloid-beta aggregation and to exert anticholinesterase and antioxidant effects. J. Med. Chem., 2014, 57, 8576-8589.
4. Hamulakova, S.; Janovec, L.; Hrabinova, M.; Spilovska, K.; Korabecny, J.; Kristian, P.; Kuca, K.; Imrich, J. Synthesis and biological evaluation of novel tacrine derivatives and tacrine-coumarin hybrids as cholinesterase inhibitors. J. Med. Chem., 2014, 57, 7073-7084.
5. Spilovska, K.; Korabecny, J.; Kral, J.; Horova, A.; Musilek, K.; Drtinova, L.; Gazova, Z.; Siposova, K.; Kuca, K. 7-methoxytacrine- adamantylamine heterodimers as cholinesterase inhibitors in AD treatment – synthesis, biological evaluation and molecular modeling studies. Molecules, 2013, 18, 2397-2418.
6. Korabecny, J.; Dolezal, R.; Cabelova, P.; Horova, A.; Hruba, E.; Ricny, J.; Sedlacek, L.; Nepovimova, E.; Spilovska, K.; Andrs, M.; Musilek, K.; Opletalova, V.; Sepsova, V.; Ripova, D.; Kuca, K. 7-MEOTA- donepezil like compounds as cholinesterase inhibitors: Synthesis, pharmacological evaluation, molecular modelling and QSAR studies. Eur. J. Med. Chem., 2014, 82, 426-438.
7. Korabecny, J.; Soukup, O.; Dolezal, R.; Spilovka, K.; Nepovimova, E.; Andrs, M.; Nguyen, T.D.; Jun, D.; Musilek, K.; Kucerova-Chlupacova, M.; Kuca, K. From pyridinium-based to centrally active acetylcholinesterase reactivators. Mini-Rev. Med. Chem., 2014, 14, 215-221.
8. Andrs, M.; Korabecny, J.; Jun, D.; Hodny, Z.; Bartek, J.; Kuca, K. Phosphatidylinositol 3-kinase (PI3K) and phosphatidylinositol 3-kinase- related kinase (PIKK) inhibitors: the importance of the morpholine ring. J. Med. Chem., 2015, 58 (1), 41-71.
9. Nepovimova, E.; Korabecny, J.; Dolezal, R. Babkova, K.; Ondrejicek, A.; Jun, D.; Sepsova, V.; Horova, A.; Hrabinova, M.; Soukup, O.; Bukum, N.; Jost, P; Muckova, L.; Kassa, J.; Malinak, D.; Andrs, M.; Kuca, K. Tacrine – trolox hybrids: A novel class of centrally active, non-hepatotoxic multi-target- directed ligands exerting anticholinesterase and antioxidant activities with low in vivo toxicity. J. Med. Chem., 2015, 58 (22), 8985-9003.
10. Prati, F.; Bergamini, C.; Fato, R.; Soukup, O.; Korabecny, J.; Andrisano, M.; Bartolini, M.; Bolognesi, M.L. Novel 8-hydroxyquinoline derivatives as multitarget compounds for the treatment of Alzheimer’s Disease. ChemMedChem., 2016, just accepted.


Main skills and expertise (up to 5)

1. Alzheimer’s disease/neurodegenerative disorders
2. neurobiology
3. medicinal chemistry
4. toxicology
5. drug design/molecular modeling


Main equipment/facilities available in the participants’ lab (up to 5)

1. Discover SP – Microwave synthesizer with autosampler
2. LC-MS system connected with a Q Exactive Plus hybrid quadrupole-orbitrap spectrometer



Short personal activity proposal for the COST Action CA15135 (max 1000 characters)

Jan Korabecny graduated from the Faculty of Pharmacy (Charles University, Prague, Czech Republic) in 2008. He finished his Ph.D. studies at the Department of Pharmaceutical Chemistry and Drug Control at the same university in 2012. Recently, he was employed at the Department of Toxicology Faculty of Military Health Sciences (University of Defence, Hradec Kralove, Czech Republic). He is currently the head of the Laboratory of Chemistry at the Department of Toxicology and Military Pharmacy and postdoctoral fellow at the Biomedical Research Center (University Hospital, Hradec Kralove, Czech Republic). His area of research is pharmaceutical/medicinal chemistry, biochemistry, and toxicology. His interests are neuroscience, especially the development of novel multi-target directed ligands for treatment of Alzheimer’s disease and antidotes for organophosphorus poisoning, as well as and anticancer agents (ATR, ATM, PI3K, mTOR, CDK7, STAT3, DNA-PK kinases modulators).


Work Group preference: score from 1 (preferred) to 4 (not preferred)

Work Group of the CA15135 COST Action Score
WG1: Development of new chemical entities 1
WG2: Selection of biological targets and assessment of biological data 1
WG3: Development of chemical databases 3
WG4: Development of Computational methods for multiple ligand design and discovery 1